We compare sulfa ted galactans from two species of red algae using specific coagulation assays and experimental models of thrombosis. These polysaccharides have an identical saccharide structure and the same size chain, but with slight differences in their sulfation patterns. As a consequence of these differences, the two sulfated galactans differ in their anticoagulant and venous antithrombotic activities. Sulfated galactan from G. crinale exhibits procoagulant and prothrombotic effects in low doses (up to 1.0 mg/kg body weight), but in high doses (>1.0 mg/kg) this polysaccharide inhibits both venous and arterial thrombosis in rats and prolongs ex vivo recalcification time. In contrast, sulfated galactan from B. occidentalis is a very potent anticoagulant and antithrombotic compound in low doses (up to 0.5 mg/Kg body weight), inhibiting venous experimental thrombosis and prolonging ex vivo recalcification time, but these effects are reverted in high doses. Only at high doses (>1.0 mg/Kg) the sulfated galactan from B. occidentalis inhibits arterial thrombosis. As with heparin, sulfated galactan from G. crinale does not activate factor XII, while the polysaccharide from B. occidentalis activates factor XII in high concentrations, which could account for its procoagulant effect at high doses on rats. Both sulfated galactans do not modify bleeding time in rats. These results indicate that slight differences in the proportions and/or distribution of sulfated residues along the galactan chain may be critical for the interaction between proteases, inhibitors and activators of the coagulation system, resulting in a distinct pattern in anti-and procoagulant activities and in the antithrombotic action.
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